Article Versions Notes

Oršić Frič V, Borzan V, Šahinović I, Borzan A, Kurbel S. Real-World Study on Vedolizumab Serum Concentration, Efficacy, and Safety after the Transition from Intravenous to Subcutaneous Vedolizumab in Inflammatory Bowel Disease Patients: Single-Center Experience. Pharmaceuticals. 2023; 16(2):239. https://doi.org/10.3390/ph16020239

Oršić Frič, Vlasta, Vladimir Borzan, Ines Šahinović, Andrej Borzan, and Sven Kurbel. 2023. "Real-World Study on Vedolizumab Serum Concentration, Efficacy, and Safety after the Transition from Intravenous to Subcutaneous Vedolizumab in Inflammatory Bowel Disease Patients: Single-Center Experience" Pharmaceuticals 16, no. 2: 239. https://doi.org/10.3390/ph16020239

Oršić Frič, V., Borzan, V., Šahinović, I., Borzan, A., & Kurbel, S. (2023). Real-World Study on Vedolizumab Serum Concentration, Efficacy, and Safety after the Transition from Intravenous to Subcutaneous Vedolizumab in Inflammatory Bowel Disease Patients: Single-Center Experience. Pharmaceuticals, 16(2), 239. https://doi.org/10.3390/ph16020239